Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
World J Surg Oncol ; 20(1): 32, 2022 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-35135563

RESUMEN

BACKGROUND: To investigate the role of transmembrane p24 trafficking protein 2 (TMED2) in lung adenocarcinoma (LUAD) and determine whether TMED2 knockdown could inhibit LUAD in vitro and in vivo. METHODS: TIMER2.0, Kaplan-Meier plotter, gene set enrichment analysis (GSEA), Target Gene, and pan-cancer systems were used to predict the potential function of TMED2. Western blotting and immunohistochemistry were performed to analyze TMED2 expression in different tissues or cell lines. The proliferation, development, and apoptosis of LUAD were observed using a lentivirus-mediated TMED2 knockdown. Bioinformatics and western blot analysis of TMED2 against inflammation via the TLR4/NF-κB signaling pathway were conducted. RESULTS: TMED2 expression in LUAD tumor tissues was higher than that in normal tissues and positively correlated with poor survival in lung cancer and negatively correlated with apoptosis in LUAD. The expression of TMED2 was higher in tumors or HCC827 cells. TMED2 knockdown inhibited LUAD development in vitro and in vivo and increased the levels of inflammatory factors via the TLR4/NF-κB signaling pathway. TMED2 was correlated with TME, immune score, TME-associated immune cells, their target markers, and some mechanisms and pathways, as determined using the TIMER2.0, GO, and KEGG assays. CONCLUSIONS: TMED2 may regulate inflammation in LUAD through the TLR4/NF-κB signaling pathway and enhance the proliferation, development, and prognosis of LUAD by regulating inflammation, which provide a new strategy for treating LUAD by regulating inflammation.


Asunto(s)
Adenocarcinoma del Pulmón , Neoplasias Pulmonares , Proteínas de la Membrana/genética , Transducción de Señal , Proteínas de Transporte Vesicular/genética , Adenocarcinoma del Pulmón/patología , Línea Celular Tumoral , Humanos , Inflamación , Neoplasias Pulmonares/patología , FN-kappa B , Receptor Toll-Like 4
2.
J Clin Lab Anal ; 34(10): e23475, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32681559

RESUMEN

BACKGROUND: To determine the diagnostic value of hematologic markers for coronavirus disease 2019 (COVID-19) and explore their relationship with disease severity. METHODS: Subjects included 190 COVID-19 patients, 190 healthy subjects, and 105 influenza pneumonia (IP) patients. COVID-19 patients were divided into the ARDS and non-ARDS groups. Routine blood examination, biochemistry indicator, days in hospital, body temperature, pneumonia severity index (PSI), CURB-65, and MuLBSTA were recorded. Correlations between variables were assessed using Spearman's correlation analysis. Receiver operating characteristic (ROC) curves were used to study the accuracy of the various diagnostic tests. RESULTS: Compared with healthy subjects, COVID-19 patients had lower white blood cell (WBC), lymphocyte, platelet, and hemoglobin levels; higher percentages of neutrophils and monocytes; lower percentages of lymphocytes and higher neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) values (P < .05). COVID-19 patients had higher WBC and neutrophil levels and lower percentages of lymphocytes compared to IP (P < .05). ROC curve analysis revealed that MLR had a high diagnostic value in differentiating COVID-19 patients from healthy subjects, but not from IP patients. NLR showed significant positive correlations with PSI, CURB-65, and MuLBSTA. Lymphocyte count was lower in the ARDS group and yielded a higher diagnostic value than the other variables. CONCLUSIONS: Monocyte-to-lymphocyte ratio showed an acceptable efficiency to separate COVID-19 patients from healthy subjects, but failed to rule out IP patients. NLR may be a reliable marker to evaluate the disease severity of COVID-19. Lymphocyte count may be useful to establish the early diagnosis of ARDS in the COVID-19 patients.


Asunto(s)
Técnicas de Laboratorio Clínico , Infecciones por Coronavirus , Recuento de Leucocitos , Pandemias , Neumonía Viral , Adulto , Betacoronavirus , Biomarcadores , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico/métodos , Técnicas de Laboratorio Clínico/normas , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/epidemiología , Estudios Transversales , Femenino , Humanos , Linfocitos/citología , Masculino , Persona de Mediana Edad , Monocitos/citología , Neutrófilos/citología , Neumonía Viral/sangre , Neumonía Viral/diagnóstico , Neumonía Viral/epidemiología , Valor Predictivo de las Pruebas , SARS-CoV-2
3.
Exp Cell Res ; 331(1): 164-175, 2015 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-25265063

RESUMEN

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by proteinaceous pulmonary edema and severe arterial hypoxemia with a mortality of approximately 40%. Stimulation of epithelial sodium channel (ENaC) promotes Na(+) transport, a rate-limiting step for pulmonary edema reabsorption. Insulin is known to participate in the ion transport; however, its role in pulmonary edema clearance and the regulatory mechanism involved have not been fully elucidated. In the current study, in a lipopolysaccharide-based mouse model of ALI, we found that insulin alleviated pulmonary edema by promoting ENaC-mediated alveolar fluid clearance through serum and glucocorticoid induced kinase-1 (SGK1). In alveolar epithelial cells, insulin increased the expression of α-, ß-, and γ-ENaC, which was blocked by the mammalian target of rapamycin complex 2 (mTORC2) inhibitor or knockdown of Rictor (a necessary component of mTORC2), and SGK1 inhibitor, respectively. In addition, an immunoprecipitation study demonstrated that SGK1(Ser422) phosphorylation, the key step for complete SGK1 activation by insulin, was conducted through PI3K/mTORC2 pathway. Finally, we testified the role of mTORC2 in vivo by demonstrating that PP242 prevented insulin-stimulated SGK1 activation and ENaC increase during ALI. The data revealed that during ALI, insulin stimulates alveolar fluid clearance by upregulating the expression of α-, ß-, and γ-ENaC at the cell surface, which was, at least, partially through activating mTROC2/SGK1 signaling pathway.


Asunto(s)
Lesión Pulmonar Aguda/metabolismo , Modelos Animales de Enfermedad , Canales Epiteliales de Sodio/metabolismo , Proteínas Inmediatas-Precoces/metabolismo , Insulina/farmacología , Complejos Multiproteicos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Alveolos Pulmonares/metabolismo , Serina-Treonina Quinasas TOR/metabolismo , Lesión Pulmonar Aguda/tratamiento farmacológico , Lesión Pulmonar Aguda/patología , Animales , Western Blotting , Canales Epiteliales de Sodio/genética , Humanos , Hipoglucemiantes/farmacología , Proteínas Inmediatas-Precoces/genética , Técnicas para Inmunoenzimas , Inmunoprecipitación , Técnicas In Vitro , Masculino , Diana Mecanicista del Complejo 2 de la Rapamicina , Ratones , Ratones Endogámicos C57BL , Complejos Multiproteicos/genética , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/genética , Alveolos Pulmonares/efectos de los fármacos , Alveolos Pulmonares/patología , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/efectos de los fármacos , Serina-Treonina Quinasas TOR/genética , Regulación hacia Arriba
4.
Respir Res ; 15: 159, 2014 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-25551628

RESUMEN

BACKGROUND: 17ß-estradiol can suppress acute lung injury (ALI) and regulate alveolar epithelial sodium channel (ENaC). However the relationship between these two functions remains unclear. This study is conducted to assess the role of ENaC and the PI3K/Akt/SGK1 signaling pathway in 17ß-estradiol therapy in attenuating LPS-induced ALI. METHODS: ALI was induced in C57BL/J male mice by intratracheal administration of lipopolysaccharide (LPS). Concurrent with LPS administration, 17ß-estradiol or sterile saline was administered to ALI model with or without the phosphoinositide 3-kinase (PI3K) inhibitor wortmannin. The lung histological changes, inflammatory mediators in bronchoalveolar lavage fluid (BALF), wet/dry weight ratio (W/D) and alveolar fluid clearance (AFC) were measured 4 hours after LPS challenge in vivo. For in vitro studies, LPS-challenged MLE-12 cells were pre-incubated with or without wortmannin for 30 minutes prior to 17ß-estradiol treatment. Expression of ENaC subunits was assessed by reverse transcriptase PCR, western blot, cell surface biotinylation, and immunohistochemistry. The levels of phosphorylated Akt and SGK1 in lung tissue and lung cell lines were investigated by western blot. RESULTS: 17ß-estradiol suppressed LPS-mediated ALI in mice by diminishing inflammatory mediators and enhancing AFC. 17ß-estradiol promoted the expression and surface abundance of α-ENaC, and increased the levels of phosphorylated-Akt and phosphorylated-SGK1 following LPS challenge. This induction was abolished by the PI3K inhibitor wortmannin in vivo and in vitro. CONCLUSION: 17ß-estradiol attenuates LPS-induced ALI not only by repressing inflammation, but also by reducing pulmonary edema via elevation of α-ENaC expression and membrane abundance. These effects were mediated, at least partially, via activation of the PI3K/Akt/SGK1 signaling pathway.


Asunto(s)
Lesión Pulmonar Aguda/prevención & control , Endotoxinas , Canales Epiteliales de Sodio/efectos de los fármacos , Estradiol/farmacología , Proteínas Inmediatas-Precoces/metabolismo , Pulmón/efectos de los fármacos , Fosfatidilinositol 3-Quinasa/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Lesión Pulmonar Aguda/inducido químicamente , Lesión Pulmonar Aguda/enzimología , Animales , Líquido del Lavado Bronquioalveolar/química , Línea Celular , Citoprotección , Modelos Animales de Enfermedad , Activación Enzimática , Canales Epiteliales de Sodio/metabolismo , Mediadores de Inflamación/metabolismo , Pulmón/enzimología , Masculino , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Inhibidores de Proteínas Quinasas/farmacología , Edema Pulmonar/inducido químicamente , Edema Pulmonar/enzimología , Edema Pulmonar/prevención & control , Transducción de Señal/efectos de los fármacos , Regulación hacia Arriba
5.
J Pers Med ; 14(1)2024 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-38248810

RESUMEN

BACKGROUND: In recent years, increasingly complex ALI protocols involving specialized, albeit laboratory-specific media have been established, while at the same time, many studies compile the data of only a few ALI donors in spite of site-, protocol- and donor-specific differentiation. METHODS: We describe a simple morphology scoring protocol using histology material derived from epithelia grown on ALI inserts in parallel to other, more complex readouts. RESULTS: Among more than 100 ALI inserts derived from different donors, significant differences in layer score (p = 0.001) and goblet cell score (p = 0.002) were observed when ALI epithelia derived from explanted lung material were compared to trachea-derived ALI cultures. Cortisol withdrawal for the final 2 days of ALI cultures influenced goblet cell density (p = 0.001). CONCLUSIONS: While the histology score provides less resolution than FACS- or OMICs- based single cell analyses, the use of a subportion of the ALI epithelia grown on inserts makes it feasible to combine morphology assessment and other readouts of the same insert. This allows us to control for basic ALI morphology in research and personalized medicine settings in order to assess and, if desired, control for the impact of ALI culture protocols, site- and donor-specific influences on outcome of studies of ALI-derived epithelia.

6.
Medicine (Baltimore) ; 101(39): e30195, 2022 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-36181003

RESUMEN

BACKGROUND: This meta-analysis aimed to evaluate the efficacy and safety of dexamethasone in the treatment of acute respiratory distress syndrome (ARDS). METHODS: A systematic search of electronic databases was carried out from inception to May 1, 2022, including PUBMED, EMBASE, Cochrane Library, Wangfang, VIP, and CNKI. Other searches were also checked for dissertations/theses and the reference lists of the included studies. Two team members examined all citations and selected eligible articles. Randomized controlled trials (RCTs) reporting the efficacy and safety of dexamethasone for the treatment of ARDS were included, and the quality of eligible RCTs was assessed using the Cochrane Risk of Bias Tool. If necessary, we conducted data synthesis and meta-analysis. The primary outcome was all-cause mortality. Secondary outcomes were mechanical ventilation duration (day), ventilator-free status at 28 days; intensive care unit (ICU) free (day), ICU mortality, hospital mortality, sequential organ failure assessment (SOFA) as mean and range, SOFA as No. of patients, peak airway pressure (cmH2O), arterial oxygen pressure (mm Hg), days with PaO2 > 10kPa, PaO2, and the occurrence rate of adverse events. RESULTS: Four studies involving 702 patients were included in this analysis. This study showed that dexamethasone could significantly reduce all-cause mortality (odds ratio (OR) = 0.62, 95% confidence interval (CI) [0.44, 0.88], I2 = 30%, P < .001), and decrease ventilator-free status at 28 days (MD = 3.65, 95% CI [1.49, 5.80], I2 = 51%, P < .001). No significant differences in occurrence rates of adverse events were found between dexamethasone and routine or standard care. CONCLUSIONS: Evidence from the meta-analysis suggests that dexamethasone is an effective and relatively safe treatment for all-cause mortality and ventilator-free status at 28 days in patients with ARDS. Owning to the small number of eligible RCTs, the conclusions of present study are warranted in the future study.


Asunto(s)
Síndrome de Dificultad Respiratoria , Dexametasona/uso terapéutico , Humanos , Unidades de Cuidados Intensivos , Oxígeno , Respiración Artificial , Síndrome de Dificultad Respiratoria/tratamiento farmacológico
7.
Nan Fang Yi Ke Da Xue Xue Bao ; 34(9): 1282-5, 2014 Aug.
Artículo en Zh | MEDLINE | ID: mdl-25263359

RESUMEN

OBJECTIVE: To investigate the protective effect of rutin against acute lung injury induced by lipopolysaccharide (LPS). METHODS: Thirty C57BL/6 mice were randomly divided into control group, LPS-induced acute lung injury model group and treatment (LPS+Rutin) group. The pathological changes of the lung tissue were observed microscopically on paraffin sections with HE staining, and the lung wet/dry weight ratio was measured. The levels of TNF-α and IL-1ß in the bronchoalveolar lavage fluid (BALF) were measured with ELISA, and the expressions of α-ENaC were detected with RT-PCR and Western blotting. RESULTS: Pathological examination of the lung tissue revealed distinct inflammation, congestion and edema in the model group. The mice in the treatment group showed significantly milder lung injuries than those in the model group. Compared with the control group, the model group showed significantly increased lung wet/dry ratio and contents of TNF-α and IL-1ß in BALF but lowered expressions of α-ENaC mRNA and protein. Compared with the model group, rutin treatment significantly decreased the lung wet/dry ratio and TNF-α and IL-1ß levels in the BALF and increased the expressions of α-ENaC mRNA and protein. CONCLUSION: Rutin can inhibit the pulmonary inflammation and increase the expression of alveolar epithelial sodium channel protein to alleviate LPS-induced acute lung injury in mice.


Asunto(s)
Lesión Pulmonar Aguda/tratamiento farmacológico , Canales Epiteliales de Sodio/metabolismo , Rutina/farmacología , Lesión Pulmonar Aguda/inducido químicamente , Animales , Líquido del Lavado Bronquioalveolar , Interleucina-1beta/metabolismo , Lipopolisacáridos , Pulmón/patología , Ratones , Ratones Endogámicos C57BL , ARN Mensajero , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA